N
TRDA icon

Natixis’s Entrada Therapeutics TRDA Stock Holding History

Natixis’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-31,186
Closed -$433K – 1156
2024
Q1 		$433K Hold
31,186
– – ﹤0.01% 652
2023
Q4 		$517K Hold
31,186
– – ﹤0.01% 608
2023
Q3 		$505K Hold
31,186
– – ﹤0.01% 604
2023
Q2 		$468K Hold
31,186
– – ﹤0.01% 649
2023
Q1 		$444K Buy
31,186
+5,000
+19% +$66.8K ﹤0.01% 639
2022
Q4 		$354K Buy
+26,186
New +$459K ﹤0.01% 757

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return

Natixis's TRDA Position: Q2 2024 in Review

Natixis sold out of Entrada Therapeutics (TRDA) in Q2 2024, closing a stake of 31,186 shares — an estimated $433K sold.

Natixis first reported a position in TRDA in Q4 2022 and held it in 6 quarters. The position peaked at $517K in Q4 2023. 84 funds tracked by Wall St. Rank hold TRDA as of Q2 2024.

  • Natixis reported no remaining Entrada Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Natixis sold 31,186 Entrada Therapeutics shares in Q2 2024, an estimated $433K.
  • Natixis first reported a position in Entrada Therapeutics in Q4 2022 and held it in 6 quarters.
  • Natixis's Entrada Therapeutics position peaked at $517K in Q4 2023.
  • 84 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2024.

Based on Natixis's 13F filing for Q2 2024, filed 13 Aug 2024.